Therapeutically, complement mediators C3a and C5a, and their respective receptors C3aR and C5aR, displays diverse activities during the course of disease progression and drugs that specifically targets C3a, C3aR, C5, C5a or C5aR could serve as potential therapeutic options for asthma treatment in future (Fig. 3) [32]. This evidence concerns the gene C3 and asthma.